A wearable-enabled, AI-powered platform that analyzes physiological signals, delivers remote monitoring, early detection and personalized allergy insights for families and individuals living with life-threatening allergies1.
Our
Partners:
%20-%20Copy.png)
And in research collaboration with the Consortium of Food Allergy Research (CoFAR)
We continuously monitor physiological data uploaded from smart wearables
By leveraging large-scale clinical data, as well as real-world data analysis and AI, Anjo's patent-pending solution learns and adapts to your child's health and behavior. It detects distress or early signs of allergic reactions, providing parents and physicians with crucial data to make informed decisions.
Empower parents and individuals with data-driven insights for informed decisions and peace of mind. This comprehensive view of physiological data will also enable physicians to make improved care decisions.
Anjo's model detects a child reacting to small quantity of allergen 1 hour
before a severe reaction (during an Oral Food Challenge)
Anjo's Model predicts a severe allergic reaction during Oral Food Challenge (OFC) before clinical symptoms.
Anjo translates physiological data into actionable allergy alerts and insights.
Anjo.ai: Beyond Detection
Anjo identifies daily risk factors that may increase the likelihood of severe allergic reactions, including environmental, seasonal, or health-related triggers, to keep you informed.
Anjo can let you know if your child remains within recommended guidelines of sleep, movement and other wellness aspects.
If you or your child accidentally misplaced or forgot their Epinephrine Auto Injector, we will notify you immediately.
Anjo.ai provides an advanced allergic reactions event log for review by your allergist. Suspected reactions can also be manually logged, offering comprehensive tracking for personal or professional use.
Unpredictable & Deadly:
0
%
97’-08’
0
%
07’-16’
0
%
01’-12’
33M
Adults
Children
Not yet. This capability is currently in development and will be released as part of AnjoProtect™.
AnjoConnect™ is a consumer wellness product for connectivity, monitoring and awareness. AnjoProtect™ is a regulated medical product in development, intended to provide clinical-grade decision support, alerting, and guidance.
AnjoConnect™ keeps families connected, even when they're apart. Caregivers managing severe allergies can call or text their child anytime, send a quick wellness check-in, and view their child's biosignals on demand. AnjoConnect™ also monitors in the background and lets caregivers know when something looks different from their child's usual pattern, so they can reach out exactly when it matters most.
AnjoConnect™ continuously monitors physiological signals such as heart rate, heart rate variability, skin temperature, motion, and other metrics that can be collected from advanced wearable devices, giving families visibility into general wellness patterns related to allergy.
AnjoProtect™ uses advanced algorithms and AI to process metrics collected from advanced wearable devices, together with personalization and adaptation, to produce appropriate alerts and personalized insights for allergy management.
ABIE (Anjo Biosignal Intelligence Engine) is the underlying technology that analyzes raw biosensor data to identify patterns of interest for future severe allergic reaction recognition.
AnjoConnect™ is a general wellness product. It is not currently marketed or intended as a medical device. AnjoProtect™, powered by ABIE (Anjo Biosignal Intelligence Engine), is in development with the goal of FDA clearance as a SaMD. It is not yet available and has not received FDA clearance.
Yes. The watch runs on Samsung Galaxy hardware with Anjo's custom AnjoOS, but the companion Anjo app is available for both iPhone and Android. Parents and caregivers can view alerts, vitals, and stay connected to their child's device regardless of which phone they carry.
Anjo uses a wearable biosensor, currently based on a smartwatch platform, to continuously collect physiological data.
Your watch, with the Anjo-specific software, will be delivered in May 2027.
Anjo is designed for families and individuals managing food allergies, as well as clinical researchers and institutions studying allergic reactions.
Yes. Anjo's infrastructure is built to be HIPAA compliant, and your data remains secure in accordance with our privacy policy. View our Privacy Policy
Yes. Anjo is currently deployed across multiple institutions as part of a federally funded, multi-site study on oral food challenge biomarkers.
AnjoProtect™ is in active development with leading research institutions. A specific release date has not yet been set.
Families interested in early access can join the AnjoConnect™ presale or sign up for updates on our website.
Important information
1. Anjo is a decision support tool designed to help families and individuals manage life-threatening allergies. It is not intended to diagnose, treat, cure, or prevent any disease and does not replace the advice of a physician, prescribed epinephrine, or emergency care. Early detection features are in development and not yet available. In an emergency, call 911.
2. Caregiver Sharing includes up to three (3) caregivers per account. Additional caregivers are available for an additional fee.
3. The Interactive Action Plan is expected to be released later in 2027.
4. The 911-Ready Health Profile is available only with a Premium subscription. Pricing and details will be released in 2027.
5. Anaphylaxis Detection and Alerting is a future feature currently in development. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA) and is not currently available. It is intended as a decision support tool and is not designed to be a diagnostic device.
